Becton Dickinson
BDX
$180.16
-0.08%
Becton, Dickinson and Company (BDX) is a global medical technology company that manufactures and sells a broad portfolio of medical devices, instrument systems, and reagents, organized into four business units: Medical Essentials (35% of sales), Connected Care (24%), Biopharma Systems (13%), and Interventional (29%). Following the separation of its life science segment, BDX operates as a scaled medtech platform with leading positions in catheters, syringes, infection prevention, infusion pumps (Alaris), dispensing systems (Pyxis), prefillable syringes, and surgical and vascular products, deriving over 60% of revenue from the United States. The current investor narrative centers on the company's post-separation portfolio transformation, a Q2 FY2026 earnings beat with a raised full-year profit outlook, and the appointment of a new CFO, balanced against a revenue decline of 9.55% year-over-year in the most recent quarter and a stock that has lagged the broader market significantly over the past year. Analysts remain cautiously constructive, with a consensus buy rating but a wide target range that reflects debate over whether margin expansion and portfolio reshaping can offset top-line softness and competitive pressures in core device markets.…
BDX
Becton Dickinson
$180.16
Related headlines
Investment Opinion: Should I buy BDX Today?
BDX is rated a Hold. The core thesis is that the stock is attractively valued on a forward basis (13.29x forward PE) with a defensive profile and a 2.84% dividend yield, but significant revenue declines and earnings volatility warrant caution until a clear turnaround emerges. The analyst consensus is Buy with an average target of $195.67, implying 10.7% upside, but the wide target range and recent underperformance suggest limited near-term catalysts. Supporting evidence includes the forward PE of 13.29x, which is well below the trailing PE of 25.20x and near the low end of the historical range, suggesting undervaluation if earnings materialize. The dividend yield of 2.84% and payout ratio of 71.3% provide income support, while the low beta of 0.276 offers downside protection. However, the 9.55% revenue decline and net margin of 7.57% highlight operational challenges. The stock trades at a PB of 1.66x, near the low end of its historical range, which could signal value. Risks include the potential for further revenue declines, margin compression, and failure to meet the ambitious EPS estimate of $16.28. The rating would upgrade to Buy if revenue growth turns positive and margins expand, or downgrade to Sell if revenue declines accelerate or the dividend is cut. Relative to its history and peers, BDX appears undervalued on a forward basis but faces significant execution risk.
Sign up to view all
BDX 12-Month Price Forecast
BDX presents a mixed picture: the forward valuation is attractive, and the defensive profile with a solid dividend appeals to risk-averse investors. However, the significant revenue decline and earnings volatility create uncertainty. The base case (55% probability) assumes a gradual recovery and a target range of $185-$200, aligned with the analyst average. The bull case (25%) hinges on successful execution and multiple expansion, while the bear case (20%) reflects the risk of a retest of lows. I would upgrade to bullish if revenue growth turns positive and margins expand, and downgrade to bearish if revenue declines accelerate or the dividend is cut.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Becton Dickinson's 12-month outlook, with a consensus price target around $194.08 and implied upside of +7.7% versus the current price.
Average Target
$194.08
0 analysts
Implied Upside
+7.7%
vs. current price
Analyst Count
—
covering this stock
Price Range
$165 - $225
Analyst target range
BDX is covered by 12 analysts, with a consensus recommendation of 'Buy' (recommendation mean of 2.07, where 1 is Strong Buy and 5 is Strong Sell). The average target price is $195.67, implying an upside of approximately 10.7% from the current price of $176.80. The consensus leans moderately bullish, but the distribution of ratings shows a mix: recent institutional ratings include Buy/Overweight from Citigroup, Evercore ISI, and Barclays, while several firms maintain Neutral/Hold ratings (B of A, RBC, Wells Fargo, Piper Sandler, TD Cowen). This split suggests that while some analysts see value, others remain cautious due to execution risks and the revenue decline. The target price range spans from a low of $170.00 to a high of $225.00, a spread of $55 (32% of the low target). The high target of $225 assumes successful execution of the portfolio transformation, margin expansion, and a return to revenue growth, potentially driven by new product launches and operational efficiencies. The low target of $170 (just below the current price) prices in continued top-line pressure, margin compression, and a challenging competitive environment. The wide spread indicates high uncertainty and divergent views on the company's turnaround prospects. The estimated EPS average of $16.28 for the forward year is a key driver; if achieved, it would represent a massive improvement from the current TTM EPS, but the low estimate of $15.99 and high of $16.88 show relatively tight earnings expectations. The lack of recent upgrades (most actions are reiterations) suggests analysts are in a wait-and-see mode, and the stock's low beta and defensive characteristics may appeal to income-oriented investors, but the revenue decline remains a significant overhang.
Bulls vs Bears: BDX Investment Factors
The bear case currently has stronger evidence due to the significant revenue decline of 9.55% year-over-year, earnings volatility, and the stock's substantial underperformance relative to the market. However, the bull case rests on a compelling forward valuation (13.29x forward PE), a defensive low-beta profile, and a consensus Buy rating with 10.7% upside to the average target. The most critical tension is whether the company can return to revenue growth and achieve the ambitious EPS estimate of $16.28, which would justify the forward multiple and drive the stock higher. If revenue stabilizes and margins expand, the stock could re-rate; if not, the downside could be significant given the already low forward PE.
Bullish
- Attractive Forward Valuation: The forward PE of 13.29x is significantly below the trailing PE of 25.20x and near the low end of the historical PE range (16.9x-42.1x), implying substantial earnings growth. With estimated EPS of $16.28, the stock trades at a discount to its own history and potentially to peers.
- Strong Analyst Consensus and Upside: 12 analysts rate BDX a 'Buy' with an average target price of $195.67, representing 10.7% upside from the current price of $176.80. The high target of $225 suggests 27.3% upside if the turnaround succeeds.
- Defensive Low-Beta Profile: BDX has a beta of 0.276, meaning it is roughly 72% less volatile than the market. This defensive characteristic appeals to risk-averse investors and provides downside protection during market turbulence.
- Robust Cash Flow and Dividend: The company generates $2.606 billion in trailing free cash flow and pays a dividend yield of 2.84%, supported by a payout ratio of 71.3%. This offers income and financial flexibility.
Bearish
- Significant Revenue Decline: Q3 FY2026 revenue fell 9.55% year-over-year to $4.983 billion, reflecting headwinds from the life science separation and core market pressures. This top-line contraction raises concerns about growth prospects.
- Earnings Volatility and Margin Pressure: Q2 FY2026 posted a net loss of $311 million due to one-time expenses, highlighting earnings instability. Operating margin of 13.31% and net margin of 7.57% are below historical norms, indicating cost pressures.
- Underperformance and Relative Weakness: BDX has declined 7.72% over the past year while the S&P 500 gained 15.01%, resulting in a relative strength of -22.73%. The stock also has a negative 1-month change of -5.72%, showing recent weakness.
- High Dividend Payout Ratio: The payout ratio of 71.3% is elevated relative to earnings, which could limit flexibility for reinvestment or dividend increases if earnings remain under pressure. This is particularly concerning given the revenue decline.
BDX Technical Analysis
BDX is in a recovery phase within a broader range-bound consolidation, with the current price of $176.80 sitting at approximately 75.2% of its 52-week range (low of $127.59, high of $193.07). The 1-year price change of -7.72% contrasts sharply with the S&P 500's +15.01% over the same period, producing a relative strength of -22.73% and indicating significant underperformance. This positioning near the upper-middle of the range suggests the stock has recovered from its lows but has not yet reclaimed its highs, leaving room for either a breakout or a retest of support. Recent momentum is mixed: the 1-month change of -5.72% shows a pullback, while the 3-month change of +11.84% and 6-month change of +14.43% confirm a medium-term uptrend. The 1-month decline diverges from the 3-month and 6-month gains, signaling a temporary consolidation or profit-taking phase rather than a trend reversal, especially given the stock's low beta of 0.276, which implies it is roughly 72% less volatile than the market. Key technical levels are defined by the 52-week low at $127.59 as major support and the 52-week high at $193.07 as resistance. A breakout above $193 would signal renewed momentum and potentially attract trend-following capital, while a breakdown below $127.59 would indicate a deeper bearish shift. The low beta of 0.276 suggests the stock is defensive and less sensitive to market swings, which may appeal to risk-averse investors but also means it may lag in strong bull markets. The max drawdown of -33% over the past year highlights the stock's vulnerability during periods of stress, despite its low beta.
Beta
0.28
0.28x market volatility
Max Drawdown
-33.0%
Largest decline past year
52-Week Range
$128-$193
Price range past year
Annual Return
-6.4%
Cumulative gain past year
| Period | BDX Return | S&P 500 |
|---|---|---|
| 1m | -2.5% | +0.9% |
| 3m | +19.4% | +3.4% |
| 6m | +16.8% | +14.4% |
| 1y | -6.4% | +16.2% |
| ytd | -7.6% | +14.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
BDX Fundamental Analysis
BDX's revenue trajectory is under pressure, with the most recent quarter (Q3 FY2026, ended June 30, 2026) reporting revenue of $4.983 billion, a year-over-year decline of 9.55%. This follows Q2 FY2026 revenue of $4.714 billion and Q1 FY2026 revenue of $5.252 billion, indicating a sequential decline from Q1 to Q2 and a modest rebound in Q3. The revenue segments show Medical at $2.4 billion and Life Sciences at $2.5 billion, but the overall top-line contraction suggests headwinds in core device markets or the impact of the life science separation. The 9.55% YoY decline is a significant deceleration from prior periods, and the investment case now hinges on whether new product cycles and the reshaped portfolio can restore growth. Profitability remains positive but strained: Q3 FY2026 net income was $377 million, with a net margin of 7.57% and a gross margin of 46.46%. The gross margin has been relatively stable around 45-47% over recent quarters, but the operating margin of 13.31% and net margin of 7.57% are below the company's historical norms, reflecting cost pressures and restructuring charges. The Q2 FY2026 net loss of $311 million (due to a large one-time expense) underscores earnings volatility, though the Q3 rebound to profitability is encouraging. The balance sheet shows a debt-to-equity ratio of 0.755, a current ratio of 1.113, and a free cash flow TTM of $2.606 billion. The company generates substantial operating cash flow ($652 million in Q3 FY2026) but also carries significant debt and has been actively repurchasing shares ($2.25 billion in Q3) and paying dividends ($875 million in Q3). The dividend yield of 2.84% and payout ratio of 71.3% indicate a commitment to shareholder returns, but the high payout ratio relative to earnings could limit flexibility if earnings remain under pressure. ROE of 6.61% and ROA of 4.34% are modest, suggesting room for operational improvement.
Quarterly Revenue
$5.0B
2026-06
Revenue YoY Growth
-9.6%
YoY Comparison
Gross Margin
46.5%
Latest Quarter
Free Cash Flow
$2.6B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is BDX Overvalued?
Given that BDX reported positive net income in the trailing twelve months (TTM), the PE ratio is the primary valuation metric. The trailing PE is 25.20x, while the forward PE is 13.29x, a significant gap that implies the market expects substantial earnings growth in the coming year. This forward PE is based on estimated EPS of $16.28, which is a dramatic increase from the current TTM EPS of $0.04 (likely distorted by one-time items), suggesting that analysts anticipate a normalization of earnings. The PEG ratio of -37.04 is not meaningful due to negative earnings growth in the TTM period. Compared to the industry average, BDX's forward PE of 13.29x appears attractive, but without a specific industry average provided, we note that the medical instruments sector typically trades at a premium. The PS ratio of 1.93x and EV/EBITDA of 12.21x are moderate, while the PB ratio of 1.66x is below the sector average, potentially indicating undervaluation relative to book value. The dividend yield of 2.84% is above the sector median, offering income support. Historically, BDX's PE ratio has ranged from 16.9x to 42.1x over the past three years, with the current trailing PE of 25.20x sitting in the middle of that range. The forward PE of 13.29x is near the low end of the historical band, suggesting that if earnings meet expectations, the stock could be undervalued. However, the wide gap between trailing and forward PE also reflects uncertainty around the earnings recovery. The PB ratio of 1.66x is near the low end of its historical range (1.53x to 2.29x), which could signal a value opportunity or reflect concerns about asset quality.
PE
25.2x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 17x~55x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
12.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks for BDX are significant. The company carries a debt-to-equity ratio of 0.755 and a current ratio of 1.113, indicating a leveraged balance sheet with limited short-term liquidity. The revenue decline of 9.55% year-over-year in Q3 FY2026, coupled with a net margin of just 7.57% and operating margin of 13.31%, highlights margin pressure and earnings volatility. The Q2 FY2026 net loss of $311 million, driven by one-time expenses, underscores the potential for further earnings surprises. Additionally, the high dividend payout ratio of 71.3% and share repurchases ($2.25 billion in Q3) may strain cash flows if earnings do not recover. The company's ROE of 6.61% and ROA of 4.34% are modest, suggesting operational inefficiencies. Market and competitive risks are also pronounced. BDX operates in a highly competitive medical device industry, and its core markets face pricing pressure and technological disruption. The stock's low beta of 0.276 offers some insulation from market swings, but it also means the stock may lag in strong bull markets. The valuation, while attractive on a forward basis (13.29x), could compress if earnings disappoint. The wide analyst target range ($170-$225) reflects uncertainty, and recent news of a Q2 beat and raised outlook was met with analyst skepticism, indicating that execution risks remain. Regulatory changes and healthcare policy shifts could also impact demand. The worst-case scenario involves a continued revenue decline, failure to achieve the estimated EPS of $16.28, and multiple compression. In such a scenario, the stock could retest its 52-week low of $127.59, representing a 27.8% decline from the current price of $176.80. The max drawdown over the past year was -33%, indicating that a similar drawdown could occur if the turnaround stalls. The analyst low target of $170 is only 3.8% below the current price, but a more severe bear case could see the stock fall to the low $130s, especially if macro conditions worsen or competitive pressures intensify.
FAQ
The key risks include: 1) Financial risk: high debt-to-equity of 0.755 and a current ratio of 1.113, with a dividend payout ratio of 71.3% that may strain cash flow if earnings decline. 2) Operational risk: revenue declined 9.55% YoY in Q3 FY2026, and margins are under pressure (net margin 7.57%). 3) Competitive risk: the medical device industry is highly competitive, and BDX faces pricing pressure and technological disruption. 4) Market risk: the stock has underperformed the S&P 500 by 22.73% over the past year, and its low beta may cause it to lag in bull markets. The most severe risk is a continued revenue decline leading to a retest of the 52-week low of $127.59.
The 12-month forecast has three scenarios: Bull case (25% probability) targets $210-$225, assuming successful turnaround and EPS growth. Base case (55% probability) targets $185-$200, assuming gradual recovery and EPS of $16.28. Bear case (20% probability) targets $130-$150, assuming continued revenue declines and margin compression. The base case is most likely, with the key assumption that revenue stabilizes and the company meets earnings expectations. The analyst average target of $195.67 aligns with the base case.
BDX appears undervalued on a forward basis. The forward PE of 13.29x is well below the trailing PE of 25.20x and near the low end of its historical range (16.9x-42.1x). The PB ratio of 1.66x is also near the low end of its historical range (1.53x-2.29x). The PS ratio of 1.93x and EV/EBITDA of 12.21x are moderate. The market is pricing in a significant earnings recovery, as evidenced by the gap between trailing and forward PE. If the company achieves the estimated EPS of $16.28, the stock could be undervalued. However, the revenue decline and margin pressure introduce uncertainty, so the valuation reflects a discount for execution risk.
BDX may be a good buy for income-oriented, risk-averse investors, given its 2.84% dividend yield and low beta of 0.276. The stock trades at a forward PE of 13.29x, which is attractive if earnings meet the consensus estimate of $16.28. Analysts have a Buy rating with an average target of $195.67, implying 10.7% upside. However, the 9.55% revenue decline and earnings volatility are significant concerns. The biggest downside risk is a retest of the 52-week low of $127.59, representing a 27.8% decline. Therefore, it is a good buy only for those with a long-term horizon and tolerance for near-term volatility, ideally accumulating on dips.
BDX is more suitable for long-term investment, given its defensive characteristics, dividend yield, and ongoing turnaround. The low beta of 0.276 and 2.84% dividend yield appeal to income-focused investors. However, the revenue decline and earnings volatility make it less ideal for short-term trading, as near-term catalysts are limited. A minimum holding period of 2-3 years is suggested to allow the portfolio transformation to materialize and for earnings to recover. Short-term traders might exploit volatility around earnings, but the risk/reward is less favorable.